Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Short Interest Update

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) was the recipient of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 101,700 shares, an increase of 32.4% from the October 15th total of 76,800 shares. Based on an average daily volume of 1,851,000 shares, the days-to-cover ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock traded down $0.22 on Thursday, hitting $5.36. The stock had a trading volume of 3,506,472 shares, compared to its average volume of 1,362,203. The stock has a market cap of $21.06 billion, a price-to-earnings ratio of -20.62 and a beta of 1.10. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Bayer Aktiengesellschaft has a 52-week low of $5.33 and a 52-week high of $11.33. The company’s 50 day moving average price is $7.39 and its 200 day moving average price is $7.42.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.10). The firm had revenue of $10.96 billion during the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. On average, research analysts anticipate that Bayer Aktiengesellschaft will post 1.43 EPS for the current year.

Analyst Ratings Changes

Separately, Bank of America upgraded shares of Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One research analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.